Why the study?
Does ginsenoside-Rb2 improve hyperlipemia and diabetic ketoacidosis in streptozotocin-induced diabetic rats?
Does ginsenoside-Rb2 improve hyperlipemia and diabetic ketoacidosis in streptozotocin-induced diabetic rats?
Ginsenoside-Rb2 demonstrates lipid-lowering and anti-ketoacidosis effects in a diabetic rat model.
Animal data on ginsenoside-Rb2 merit human translation studies; does not support clinical use in diabetic dyslipidemia or ketoacidosis.
The effect of ginsenoside-Rb2 purified from ginseng was investigated in streptozotocin-induced diabetic rats. The rats treated with ginsenoside-Rb2 showed significant decreases in triglyceride, non-esterified fatty acid, and total cholesterol in the serum. A lipid-improving action in the serum was observed in rats with hyperlipemia. Furthermore, the lipolytic activity of lipoprotein lipase was stimulated with a concomitant decrease in the levels of triglyceride and very low density lipoprotein in the serum, while a repressive effect on hormone-sensitive lipase activity was observed. The accumulation of lipid in the adipose tissue was also observed. In addition to the hypolipemic effect, ginsenoside-Rb2 exhibited a lowering action on the serum levels of 3-hydroxybutyrate and acetoacetate in streptozotocin-induced diabetic rats, indicating an improvement of diabetic ketoacidosis.
No takes yet. Share an insight, caveat, or question.
Yokozawa et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: